Advertisement

The “hypointense substantia nigra” sign. A novel MRI marker of progressive supranuclear palsy

Published:December 20, 2020DOI:https://doi.org/10.1016/j.jns.2020.117286

      Highlights

      • The “hypointense substantia nigra sign” (HSNS) is a novel MRI sign present in PSP.
      • The HSNS is a well-defined hypointense area at the medial substantia nigra in T1 images.
      • The HSNS is highly specific for progressive supranuclear palsy (PSP).
      • The HSNS is more specific but less sensitive for PSP compared to the “Hummingbird sign”.

      Keywords

      Abbreviations:

      PSP (progressive supranuclear pasly), NPH (normal pressure hydrocephalus), HSN (hypointense substatnia nigra), PD (Parkinson's disease), MSA (multiple system atrophy), CBD (corticobasal degeneration), PSP-HSN (PSP with HSN sign), PSP-nHSN (PSP without HSN sign), SN (substantia nigra), SNr (substantia nigra pars reticulata), SNc (substantia nigra pars compacta.)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hoglinger G.U.
        • et al.
        Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria.
        Mov. Disord. 2017; 32: 853-864
        • Williams D.R.
        • et al.
        Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy.
        Mov. Disord. 2007; 22: 2235-2241
        • Williams D.R.
        • et al.
        Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism.
        Brain. 2005; 128: 1247-1258
        • Constantinides V.C.
        • et al.
        Midbrain morphology in idiopathic normal pressure hydrocephalus: A progressive supranuclear palsy mimic.
        Acta Neurol Scand. 2020; 141: 328-334
        • Constantinides V.C.
        • et al.
        MRI Planimetry and Magnetic Resonance Parkinsonism Index in the Differential Diagnosis of Patients with Parkinsonism.
        AJNR Am J Neuroradiol. 2018; 39: 1047-1051
        • Constantinides V.C.
        • et al.
        Simple linear brainstem MRI measurements in the differential diagnosis of progressive supranuclear palsy from the parkinsonian variant of multiple system atrophy.
        Neurol. Sci. 2018; 39: 359-364
        • Pyatigorskaya N.
        • et al.
        Multimodal magnetic resonance imaging quantification of brain changes in progressive supranuclear palsy.
        Mov. Disord. 2020; 35: 161-170
        • Hoglinger G.U.
        • et al.
        Longitudinal magnetic resonance imaging in progressive supranuclear palsy: a new combined score for clinical trials.
        Mov. Disord. 2017; 32: 842-852
        • Kato N.
        • Arai K.
        • Hattori T.
        Study of the rostral midbrain atrophy in progressive supranuclear palsy.
        J. Neurol. Sci. 2003; 210: 57-60
        • Itolikar S.M.
        • Salagre S.B.
        • Kalal C.R.
        ‘Hummingbird sign’, ‘penguin sign’ and ‘Mickey mouse sign’ in progressive supranuclear palsy.
        J. Assoc. Physicians India. 2012; 60: 52
        • Adachi M.
        • et al.
        Morning glory sign: a particular MR finding in progressive supranuclear palsy.
        Magn. Reson. Med. Sci. 2004; 3: 125-132
        • Armstrong M.J.
        • et al.
        Criteria for the diagnosis of corticobasal degeneration.
        Neurology. 2013; 80: 496-503
        • Postuma R.B.
        • et al.
        MDS clinical diagnostic criteria for Parkinson’s disease.
        Mov. Disord. 2015; 30: 1591-1601
        • Gilman S.
        • et al.
        Second consensus statement on the diagnosis of multiple system atrophy.
        Neurology. 2008; 71: 670-676
        • Relkin N.
        • et al.
        Diagnosing idiopathic normal-pressure hydrocephalus.
        Neurosurgery. 2005; 57 (discussion ii-v): S4-S16
        • Hutchinson M.
        • et al.
        Spin-lattice distribution MRI maps nigral pathology in progressive supranuclear palsy (PSP) during life: a pilot study.
        PLoS One. 2014; 9: e85194
        • Hutchinson M.
        • Raff U.
        Detection of Parkinson’s disease by MRI: spin-lattice distribution imaging.
        Mov. Disord. 2008; 23: 1991-1997
        • Dexter D.T.
        • et al.
        Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia.
        Brain. 1991; 114: 1953-1975
        • Foroutan P.
        • et al.
        Progressive supranuclear palsy: high-field-strength MR microscopy in the human substantia nigra and globus pallidus.
        Radiology. 2013; 266: 280-288
        • Probst A.
        • et al.
        Progressive supranuclear palsy: extensive neuropil threads in addition to neurofibrillary tangles. Very similar antigenicity of subcortical neuronal pathology in progressive supranuclear palsy and Alzheimer’s disease.
        Acta Neuropathol. 1988; 77: 61-68
        • Hardman C.D.
        • et al.
        Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
        Exp. Neurol. 1997; 144: 183-192
        • Halliday G.M.
        • et al.
        A role for the substantia nigra pars reticulata in the gaze palsy of progressive supranuclear palsy.
        Brain. 2000; 123: 724-732
        • Sharpe J.A.
        Cortical control of eye movements.
        Curr. Opin. Neurol. 1998; 11: 31-38
        • Oyanagi K.
        • et al.
        Substantia nigra in progressive supranuclear palsy, corticobasal degeneration, and parkinsonism-dementia complex of Guam: specific pathological features.
        J. Neuropathol. Exp. Neurol. 2001; 60: 393-402
        • Fearnley J.M.
        • Lees A.J.
        Ageing and Parkinson’s disease: substantia nigra regional selectivity.
        Brain. 1991; 114: 2283-2301